Eli Lilly and Company Stock News

Eli Lilly will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer's drug and highly popular weight loss and diabetes treatments, among other medicines, in Ireland.  The pharmaceutical giant is spending $1 billion to expand an existing site in Limerick Ireland, to increase the production of certain active ingredients, including those used in its Alzheimer's treatment Kis...

Company ups manufacturing investment in Limerick by $1 billion; unveils new $800 million Kinsale facility New investment will enhance global medicine production, benefiting millions of patients worldwide INDIANAPOLIS , Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of bio...

As the high-growth trade fizzles out in September, even some top-tier secular growth plays will take an outsized hit to the chin.

Eli Lilly's experimental insulin that is injected just once a week is as effective as daily insulin injections for maintaining blood sugar levels in patients with type 1 or type 2 diabetes, researchers said on Tuesday at the European Association for the Study of Diabetes meeting in Madrid.

Eli Lilly has been an innovative force in medicine for a long time. The company is making waves for its progress in weight loss and Alzheimer's, but there is another big reason Lilly should be on your radar.

These two drugmakers have been delivering significantly above-average returns for years. Both still have excellent prospects and could decide to split their stocks as their share prices get higher.

Detailed results were published in The Lancet and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024 INDIANAPOLIS , Sept. 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-5 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec i...

In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7%  Detailed results were published in The New England Journal of Medicine and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024 INDIANAPOLIS , Sept. 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LL...